SLC5A2 and sarcopenia: Moreover, one meta-analysis specifically addressing sarcopenia-related outcomes reported that SGLT2 inhibitors therapy was associated with statistically lower muscle strength compared to controls, in addition to the LBM/SMM declines [45].